A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

Study Criteria for Patients with OA of the Knee (Cohort G1-G9) Inclusion Criteria: * Age 45 or older, non or moderate smokers, body mass index (BMI) ≤ 40.0 kg/m2. * Knee OA symptoms with confirmed mild to moderate OA. * Study knee OA severity grade 1-3 (Kellgren-Lawrence). * Agree to use contraception Exclusion Criteria: * Clinically significant (CS) abnormalities (physical, lab, hepatitis B/C, HIV, electrocardiogram \[ECG\], vital sign or unstable illness). * Positive urine drug screen, tuberculosis (TB) test; significant alcohol/drug abuse * Allergic reactions to TLC599, its components, related drugs or cosyntropin. * History of autoimmune disease, immunodeficiency diseases, treated malignancy, CS opportunistic infection, tuberculosis, infective arthritis or concurrent knee infection * Intra-articular bleeding in study knee. * Skin issues at injection site or hindrance to knee joint penetration. * Blood coagulation disorders. * Stroke or myocardial infarction * Poorly controlled hypertension or vital sign abnormalities. * Interfering conditions with dosing, visits, or compliance or refusal of synovial fluid collection. * Medication: Strong/moderate Cytochrome P450 (CYP) 3A/3A4 inhibitors/inducers, prescription meds, over-the-counter (OTC)/natural health products, meds affecting platelet function, depot injection/implant, IA corticosteroid, hyaluronic acid, or other injection in study knee, impact on endogenous steroid levels, systemic corticosteroids, live attenuated va…